June 1, 2025 08:00 AM EDT
R&D

As­traZeneca de­tails its oral SERD 'switch­ing' reg­i­men as fea­si­bil­i­ty ques­tions re­main

Max Gelman

Senior Editor

CHICA­GO — As­traZeneca is plant­i­ng its flag in the oral SERD space, tout­ing pos­i­tive Phase 3 breast can­cer da­ta for a pro­gram it ex­pects to ex­ceed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

DOGE set to­day as their last day at FDA. In­stead, they're con­tin­u­ing to get full pay and don't work

Re­gen­eron makes $80M obe­si­ty deal with Han­soh

Phase 3 or bust: Why Lil­ly won't run mid-stage can­cer tri­als

Bris­tol My­ers bets $1.5B on BioN­Tech's PD-L1xVEGF from Bio­theus

Sanofi to snap up Blue­print Med­i­cines and mas­to­cy­to­sis drug Ay­vak­it for $9.1B

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times